While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its ...